AutoPap marketing costs increase NeoPath's loss
This article was originally published in Clinica
Executive Summary
NeoPath (US) recorded sales of $374,000 in the first quarter of 1996, $350,000 of which were for its AutoPap screening system in Australia. The company reported a net loss of $8.1 million on sales of $627,000 in the first half of 1996, compared with no revenues and a loss of $6.4 million for the same period in the previous year.